Identification of JAK2 and FOXM1 expression as novel candidate biomarkers for predicting the benefit of immunotherapy in lung squamous cell carcinoma

BACKGROUND: Lung squamous cell carcinoma (LUSC) accounts for about 30% of all non-small cell lung cancers (NSCLC). However, only a small percentage of LUSC patients gain benefit from immune checkpoint inhibitors (ICIs). METHODS: This study analyzed LUSC patients from The Cancer Genome Atlas (TCGA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shixin, Liu, Shuai, Liu, Xi, Liu, Jie, Wu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339858/
https://www.ncbi.nlm.nih.gov/pubmed/34422993
http://dx.doi.org/10.21037/atm-21-2186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339858/
https://www.ncbi.nlm.nih.gov/pubmed/34422993
http://dx.doi.org/10.21037/atm-21-2186

Ejemplares similares